Oregon Cancer Institute Research Groups:Cell 616

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
Current revision (13:34, 22 March 2012) (view source)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
 +
{{Template:OHSU Knight Cancer Institute Research Groups}}
 +
 +
 +
==CELL/CANB 616 Syllabus==
{| border="1" cellpadding="2" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse; width:900px" <!-- This line here formats your table for you.  Change the code to change the formatting of your table.-->
{| border="1" cellpadding="2" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse; width:900px" <!-- This line here formats your table for you.  Change the code to change the formatting of your table.-->
| align="left" style="background:#f0f0f0;"|'''Week'''
| align="left" style="background:#f0f0f0;"|'''Week'''
Line 10: Line 14:
|1
|1
|M
|M
-
|March 28
+
|April 2
|Mutagenic Mechanisms
|Mutagenic Mechanisms
-
|Jon Oyer
+
|Mitch Turker
|
|
|--
|--
|
|
|W  
|W  
-
|March 30
+
|April 4
|Chemical Carcinogenesis/DNA Repair
|Chemical Carcinogenesis/DNA Repair
|Stephen Lloyd
|Stephen Lloyd
Line 24: Line 28:
|
|
|Th
|Th
-
|March 31
+
|April 5
-
|Autophagy, Apoptosis
+
|Cancer Stem Cells
-
|Mushui Dai
+
|Missy Wong
|
|
|--
|--
|2
|2
|M
|M
-
|April 4
+
|April 9
-
|Cancer Stem Cells
+
|Tumor Microenvironment
-
|Missy Wong
+
|Lisa Coussens
|
|
|--
|--
|
|
|W
|W
-
|April 6
+
|April 11
|Metastasis & Angiogenesis
|Metastasis & Angiogenesis
|Rosalie Sears
|Rosalie Sears
Line 45: Line 49:
|
|
|TH
|TH
-
|April 7
+
|April 12
-
|Tumor Microenvironment
+
|Imagining in Cancer
-
|Amy Skinner
+
|Charles Springer
|
|
|--
|--
|3
|3
|M
|M
-
|April 11
+
|April 16
-
|Metabolism in cancer
+
|Mutational Analysis of Solid Tumors - Sequenome
-
|Jason Link
+
|Chris Coreless
|
|
|--
|--
|
|
|W
|W
-
|April 13
+
|April 18
-
|Mutational Analysis of Solid Tumors -- sequenome
+
|Predictive Gene Signatures
-
|Chris Corless
+
|Paul Spellman
|
|
|--
|--
|
|
|Th
|Th
-
|April 14
+
|April 19
|Solid Cancer Path
|Solid Cancer Path
|Megan Troxel
|Megan Troxel
Line 73: Line 77:
|4
|4
|M
|M
-
|April 18
+
|April 23
-
|Hem Path
+
|Targeted Cancer Therapies
-
|Craig Okada
+
|Charles Lopez
|
|
|--
|--
|
|
|W
|W
-
|April 20
+
|April 25
|Immunotherapy
|Immunotherapy
|Bernie Fox
|Bernie Fox
Line 87: Line 91:
|
|
|Th
|Th
-
|April 21
+
|April 26
-
|Targeted Cancer Therapies
+
|Novel Mech. of Drug Delivery
-
|Charles Lopez
+
|Wassana Yantasee
|
|
|--
|--
|5
|5
|M
|M
-
|April 25
+
|April 30
-
|Clinical Sarcoma
+
|Lung
-
|Chris Ryan
+
|Alan Sadler
|
|
|--
|--
|
|
|W
|W
-
|April 27
+
|May 2
|Radiation Oncology
|Radiation Oncology
|Charles Thomas
|Charles Thomas
Line 108: Line 112:
|
|
|Th
|Th
-
|April 28
+
|May 3
|Kidney
|Kidney
|George Thomas
|George Thomas
Line 115: Line 119:
|6
|6
|M
|M
-
|May 2
+
|May 7
-
|Prostate
+
|Head and Neck
-
|Joshi Alumkal
+
|Neil Gross
-
|
+
|NOTE TIME AND ROOM: 10am RJH 5524
|--
|--
|
|
|W
|W
-
|May 4
+
|May 9
|Breast
|Breast
|Steve Chui
|Steve Chui
-
|
+
|NOTE TIME AND ROOM: 10am RJH 5524
|--
|--
|
|
|Th
|Th
-
|May 5
+
|May 10
-
|Underlying Molecular Context for Tumor Biology
+
|RESEARCH WEEK
-
|David Qian
+
|No class
|
|
|--
|--
|7
|7
|M
|M
-
|May 9
+
|May 14
-
|Head and Neck
+
|Ovarian
-
|Neil Gross
+
|Tanja Pejovic
|
|
|--
|--
|
|
|W
|W
-
|May 11
+
|May 16
-
|Skin
+
|Prostate
-
|Andrew Blauvelt
+
|Joshi Alumkal
|
|
|--
|--
|
|
|Th
|Th
-
|May 12
+
|May 17
-
|*****Student Research Forum*****
+
|Skin
-
|
+
|Justin Leitenberger
|
|
|--
|--
|8
|8
|M
|M
-
|May 16
+
|May 21
|GI
|GI
|Charles Lopez
|Charles Lopez
Line 164: Line 168:
|
|
|W
|W
-
|May 18
+
|May 23
|Pancreas
|Pancreas
|Gina Vacarro
|Gina Vacarro
Line 171: Line 175:
|
|
|Th
|Th
-
|May 19
+
|May 24
-
|Liver
+
|Clinical Hem. Malignancy
-
|Scott Naugler
+
|W. Harv. Fleming
|
|
|--
|--
|9
|9
|M
|M
-
|May 23
+
|May 28
-
|Clinical Hem Malignancy
+
|MEMORIAL DAY
-
|W. Harvey Fleming
+
|No Class
|
|
|--
|--
|
|
|W
|W
-
|May 25
+
|May 30
|Basic Science Hem Malignancy
|Basic Science Hem Malignancy
|Jeff Tyner
|Jeff Tyner
Line 192: Line 196:
|
|
|Th
|Th
-
|May 26
+
|May 31
|Nutrition and Cancer
|Nutrition and Cancer
|Jackie Shannon
|Jackie Shannon
Line 199: Line 203:
|10
|10
|M
|M
-
|May 30
+
|June 4
-
|*****MEMORIAL DAY NO CLASS*****
+
|Liver
-
|
+
|Scott Naugler
|
|
|--
|--
|
|
|W
|W
-
|June 1
+
|June 6
-
|Lung
+
|Brain Cancer - Adult
-
|Mark Deffebach
+
|Edward Neuwelt
|
|
|--
|--
|
|
|Th
|Th
-
|June 2
+
|June 7
-
|Tumor Board
+
|Tumor Board I
|Sears/Wong
|Sears/Wong
|
|
Line 220: Line 224:
|11
|11
|M
|M
-
|June 6
+
|June 11
|Brain Cancer - pediatric
|Brain Cancer - pediatric
|Kellie Nazemi
|Kellie Nazemi
|
|
|--
|--
-
|SPECIAL TIME
+
|  
-
'''10 -11 :30am''' 
+
|W
|W
-
|June 8
+
|June 13
-
|Brain Cancer - adult
+
|Tumor Board II
-
|Edward Neuwelt
+
|Sears/Wong
|
|
|--
|--
|
|
|Th
|Th
-
|June 9
+
|June 14
|Pediatric Cancers
|Pediatric Cancers
|Charles Keller
|Charles Keller
|
|
|}
|}
 +
 +
CELL616/CANB616 Advanced Topics in Cancer Biology Expectations
 +
Spring 2012
 +
 +
Goals of the course
 +
This upper level course will provide clinical insight into the clinical course, pathology, treatment, and therapeutic challenges that exist in a number of different organ-specific cancers. These clinical hallmarks and challenges are the important foundation on which novel basic science cancer research is built.
 +
 +
The course is designed to explore cancer mechanisms, hallmarks and novel technical approaches to unraveling underlying cancer behavior and characteristics, as well as organ-specific challenges, including current state of clinical diagnoses, treatment, prognosis and development of novel therapies. These lectures are designed to address the state of the art and to provide insight into the future of the field.
 +
 +
A critical aspect of the course is to provide the opportunity to basic science researchers to interact with clinical faculty. This will be accomplished through in class lectures, attendance at tumor-board, and shadowing with a clinical oncologist. We believe that this experience provides the opportunity to begin to understand the clinical challenges that can ultimately guide important discoveries in basic cancer research.
 +
 +
 +
Grading policy
 +
 +
Your grade will be based upon three criteria:
 +
 +
1. Class participation (30%)
 +
How interactive you are during the lecture
 +
 +
2. Your tumor board presentation (30%)
 +
 +
3. Final Exam (40%)
 +
This exam is a written 2 page review of one cancer type (your choice).
 +
 +
Within this review you will include information addressing: background on this type of cancer, demographics, current therapies, known molecular mechanisms, molecular and animal models that exist, cutting edge research being performed to elucidate the underlying molecular pathway and/or development of novel therapeutics.

Current revision

Equipped with his five senses, man explores the universe around him and calls the adventure Science.  ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Faculty        Graduate Program        Postdocs        OHSU Knight Core Facilities       



Programs     Res Group Meetings        Cancer Journal Club        Cell/CANB 616        Gen. Inst/R3 Club     CANB 610    



CELL/CANB 616 Syllabus

Week Day Date Topic Lecturer Documents
1 M April 2 Mutagenic Mechanisms Mitch Turker
W April 4 Chemical Carcinogenesis/DNA Repair Stephen Lloyd
Th April 5 Cancer Stem Cells Missy Wong
2 M April 9 Tumor Microenvironment Lisa Coussens
W April 11 Metastasis & Angiogenesis Rosalie Sears
TH April 12 Imagining in Cancer Charles Springer
3 M April 16 Mutational Analysis of Solid Tumors - Sequenome Chris Coreless
W April 18 Predictive Gene Signatures Paul Spellman
Th April 19 Solid Cancer Path Megan Troxel
4 M April 23 Targeted Cancer Therapies Charles Lopez
W April 25 Immunotherapy Bernie Fox
Th April 26 Novel Mech. of Drug Delivery Wassana Yantasee
5 M April 30 Lung Alan Sadler
W May 2 Radiation Oncology Charles Thomas
Th May 3 Kidney George Thomas
6 M May 7 Head and Neck Neil Gross NOTE TIME AND ROOM: 10am RJH 5524
W May 9 Breast Steve Chui NOTE TIME AND ROOM: 10am RJH 5524
Th May 10 RESEARCH WEEK No class
7 M May 14 Ovarian Tanja Pejovic
W May 16 Prostate Joshi Alumkal
Th May 17 Skin Justin Leitenberger
8 M May 21 GI Charles Lopez
W May 23 Pancreas Gina Vacarro
Th May 24 Clinical Hem. Malignancy W. Harv. Fleming
9 M May 28 MEMORIAL DAY No Class
W May 30 Basic Science Hem Malignancy Jeff Tyner
Th May 31 Nutrition and Cancer Jackie Shannon
10 M June 4 Liver Scott Naugler
W June 6 Brain Cancer - Adult Edward Neuwelt
Th June 7 Tumor Board I Sears/Wong
11 M June 11 Brain Cancer - pediatric Kellie Nazemi
W June 13 Tumor Board II Sears/Wong
Th June 14 Pediatric Cancers Charles Keller

CELL616/CANB616 Advanced Topics in Cancer Biology Expectations Spring 2012

Goals of the course This upper level course will provide clinical insight into the clinical course, pathology, treatment, and therapeutic challenges that exist in a number of different organ-specific cancers. These clinical hallmarks and challenges are the important foundation on which novel basic science cancer research is built.

The course is designed to explore cancer mechanisms, hallmarks and novel technical approaches to unraveling underlying cancer behavior and characteristics, as well as organ-specific challenges, including current state of clinical diagnoses, treatment, prognosis and development of novel therapies. These lectures are designed to address the state of the art and to provide insight into the future of the field.

A critical aspect of the course is to provide the opportunity to basic science researchers to interact with clinical faculty. This will be accomplished through in class lectures, attendance at tumor-board, and shadowing with a clinical oncologist. We believe that this experience provides the opportunity to begin to understand the clinical challenges that can ultimately guide important discoveries in basic cancer research.


Grading policy

Your grade will be based upon three criteria:

1. Class participation (30%) How interactive you are during the lecture

2. Your tumor board presentation (30%)

3. Final Exam (40%) This exam is a written 2 page review of one cancer type (your choice).

Within this review you will include information addressing: background on this type of cancer, demographics, current therapies, known molecular mechanisms, molecular and animal models that exist, cutting edge research being performed to elucidate the underlying molecular pathway and/or development of novel therapeutics.

Personal tools